Logo Caption

Infectious diseases products

Delivering Complete PCR Solutions for Infectious Diseases

SHARD DIAGNOSTICS™ multiplex qPCR assays for Infectious Disease detection deliver simplified workflows, reduce the risk of sample mix-ups, and increase throughput, all without compromising clinical performance. The assays can be used with either extracted material or direct samples such as blood, urine, saliva, wastewater, or swabs, eliminating the need for nucleic acid extraction and streamlining processes while supporting eco-friendly laboratory practices.

SHARD DIAGNOSTICS™ kit features

Each kit features inhibitor-tolerant reagents (lyo or liquid options) that deliver consistent amplification even from challenging or impure samples, effectively eliminating performance variability caused by the sample or extraction process. The universal chemistry supports all targets using a standardized cycling protocol, allowing multiple assays to run on the same 96-well plate. Quantified positive controls are included to standardise run performance across machines and provide quality control measures.

Solutions not just kits

Universal cycling, common fluorophores and automation compatible for fast integration.

Complete kits

Quantified controls included as standard. Optional collection tubes provided.

Advanced performance

Extraction-free for RNA & DNA with high level multiplexing. 95% LOD as low as 3 copies.

Available globally

Reagents are available in lyophilized formats for ambient shipping and are inhibitor-tolerant.

Custom Infectious Diseases Kits

AVAILABLE (RUO): Custom qPCR kits

Find out more about custom PCR kits on our dedicated pages.
Format: Inhibitor-tolerant qPCR or 1-step RT-qPCR (lyo or liquid).
Applications: Variant detection (DNA and/or RNA), gene expression, target quantification, target qualitative detection, extraction-free, rapid detection and cartridge-based system integration.
Targets: Singleplex or multiplex.
Detection method: Probe.
Shipping: Ambient.
Positive control inclusion: Yes.
Regulatory status: Research Use Only (RUO).
Sample type: Flexible (DNA, RNA or DNA/RNA combined).
Product code (SKU): SDCA_CUSTOMER LAST NAME_ORDER NUMBER.

AVAILABLE (RUO): Custom dPCR kits

Find out more about custom PCR kits on our dedicated pages.
Format: dPCR or 1-step RT-dPCR assays for combination with machine specific reagents.
Applications: Digitial PCR (dPCR) provides precise, absolute quantification for a range of applications. Shard-dx™ assays are compatible with dPCR workflows, providing minimal to no rain with strong signal. Custom assay development is available from low minimum order quantity to meet specific requirements. Each assay includes a quantified positive control to support reliable setup and consistent performance. Applications include: variant detection, gene expression, high-order multiplexing and target quantification.
Targets: Singleplex or multiplex.
Detection method: Probe.
Shipping: Ambient.
Positive control inclusion: Yes.
Regulatory status: Research Use Only (RUO).
Sample type: Flexible (DNA, RNA or DNA/RNA combined).
Product code (SKU): SDCA_CUSTOMER LAST NAME_ORDER NUMBER.

ALPHA LAUNCH (RUO): Custom amplicon sequencing kits

Find out more about custom PCR kits on our dedicated pages.
Format: Lyophilized inhibitor-tolerant PCR or 1-step RT-PCR.
Applications: Custom amplicon sequencing panels enable high-multiplex PCR enrichment for downstream sequencing workflows. Powered by LyoMorph™ chemistry, they maintain sensitivity and uniform amplification across complex samples, supporting sequencing-ready amplicons from both extracted and extraction-free inputs.
LyoMorph™-N supports extraction workflows with multiplexed amplicons up to 2kb (1 to 50 amplicons of 50-200bp or 1 to 10 amplicons of up to 2000bp).
LyoMorph™-N+ enables long-range multiplex amplification up to 50kb from extracted material (1 to 100 amplicons of 100-2000bp or 1 to 5 amplicons of up to 50,000bp).
Targets: Multiplex, long and short read.
Sample type: Flexible (DNA, RNA or DNA/RNA combined).
Shipping: Ambient.
Positive control inclusion: Yes.
Development status: Alpha launch. Ongoing optimisation via established lyophilized inhibitor tolerant shard-dx™ platforms.
Regulatory status: Research Use Only (RUO).
Alpha launch program: Join the shard-dx™ alpha launch program to generate cutting-edge kits alongside us. Find out more on the launch programs definition section on each custom page and product page.
Product code (SKU): SDCA_CUSTOMER LAST NAME_ORDER NUMBER.

Infectious Diseases Kits (qPCR)

AVAILABLE: Influenza A/B detection kit

Product name: LyoMorph-RTQ Flu A/B detection kit
Product code (SKU): SD_ID_00005
Format: 1-step RT-qPCR - lyophilized and inhibitor-tolerant (standard). Also provided in liquid format.
Potential use cases: Detection of Human Respiratory Viruses through shard-dx™ platforms may provide benefit in high-throughput or point-of-care settings either from extracted material or direct from saliva/swab with optional CE-IVD InActiv Blue® DRDP tubes (globally supplied in kits).
Targets:
- Influenza A (FAM)
- Influenza B (HEX)
- RNase P [internal control] (ATTO647N)
Limit of Detection - copies (95%): Flu A (5 copies) & Flu B (5 copies)
Detection method: Probe
Sample type: Extracted RNA, direct swab, direct saliva
Reactions: 96 / 1000
Shipping: Ambient
Number of mastermixes: 1
Number of reactions required per sample: 1
Positive control inclusion: Yes
Regulatory status: Research Use Only (RUO)

ALPHA LAUNCH: Epstein-Barr virus detection kit

Product name: LyoMorph-Q EBV detection kit
Product code (SKU): SD_ID_00004
Format: qPCR - lyophilized and inhibitor-tolerant (standard). Also provided in liquid format.
Potential use cases: Detection of Human Epstein-Barr virus through shard-dx™ platforms may provide benefit in high-throughput or point-of-care settings either direct from sample, in a cartridge or from extracted material. EBV may play a role in cancer.
Development status: Alpha launch. Product in optimisation via established shard-dx™ technology.
Targets (fluorophores to be finalised):
- EBV [all recognised variants as of official 'available (RUO)' launch date]
- RNase P [internal control]
Limit of Detection - copies (95%): ≤10 planned
Detection method: Probe
Sample type: Extracted DNA, direct blood, direct plasma
Reactions: 96 / 1000
Shipping: Ambient
Number of mastermixes: 1
Number of reactions required per sample: 1
Positive control inclusion: Yes
Regulatory status: Research Use Only (RUO)
Alpha launch program: Join the shard-dx™ alpha launch program to generate cutting-edge kits alongside us. Find out more on the launch programs definition section on each custom page and product page.

ALPHA LAUNCH: Human Papillomavirus detection kit

Product name: LyoMorph-Q HPV detection kit
Product code (SKU): SD_ID_00003
Format: qPCR - lyophilized and inhibitor-tolerant (standard). Also provided in liquid format.
Potential use cases: Detection of Human Papillomavirus through shard-dx™ platforms may provide benefit in high-throughput or point-of-care settings either direct from sample, in a cartridge or from extracted material. HPV may play a role in cancer.
Development status: Alpha aunch. Product in optimisation via established shard-dx™ technology.
Targets (fluorophores to be finalised):
- HPV 16 [all recognised variants as of official 'available (RUO)' launch date]
- HPV 18 [all recognised variants as of official 'available (RUO)' launch date]
- RNase P [internal control]
Limit of Detection - copies (95%): ≤10 planned
Detection method: Probe
Sample type: Extracted DNA, direct swab
Reactions: 96 / 1000
Shipping: Ambient
Number of mastermixes: 1
Number of reactions required per sample: TBD
Positive control inclusion: Yes
Regulatory status: Research Use Only (RUO)
Alpha launch program: Join the shard-dx™ alpha launch program to generate cutting-edge kits alongside us. Find out more on the launch programs definition section on each custom page and product page.

ALPHA LAUNCH: Sexually transmitted infections detection kit

Product name: LyoMorph-X STI detection kit
Product code (SKU): SD_ID_00006
Format: qPCR and 1-step RT-qPCR - lyophilized and inhibitor-tolerant (standard). Also provided in liquid format.
Potential use cases: Detection of Human Sexually Transmitted Infections through shard-dx™ platforms may provide benefit in high-throughput or point-of-care settings either direct from sample, in a cartridge or from extracted material.
Development status: Alpha launch. Product in optimisation via established shard-dx™ technology. In-silico development undertaken.
Targets (fluorophores to be finalised):
- Chlamydia trachomatis [all recognised variants as of official 'available (RUO)' launch date]
- Neisseria gonorrhoeae - [all recognised variants as of official 'available (RUO)' launch date]
- Mycoplasma genitalium - [all recognised variants as of official 'available (RUO)' launch date]
- Mycoplasma hominis - [all recognised variants as of official 'available (RUO)' launch date]
- Ureaplasma urealyticum - [all recognised variants as of official 'available (RUO)' launch date]
- Ureaplasma parvum - [all recognised variants as of official 'available (RUO)' launch date]
- Trichomonas vaginalis - [all recognised variants as of official 'available (RUO)' launch date]
- Herpes simplex 1 - [all recognised variants as of official 'available (RUO)' launch date]
- Herpes simplex 2 - [all recognised variants as of official 'available (RUO)' launch date]
- Gardnerella vaginalis - [all recognised variants as of official 'available (RUO)' launch date]
- RNase P [internal control]
Limit of Detection - copies (95%): ≤10 planned
Detection method: Probe
Sample type: Extracted DNA/RNA, direct urine, direct swab
Reactions: 96 / 1000
Shipping: Ambient
Number of mastermixes: 1
Number of reactions required per sample: TBD
Positive control inclusion: Yes
Regulatory status: Research Use Only (RUO)
Alpha launch program: Join the shard-dx™ alpha launch program to generate cutting-edge kits alongside us. Find out more on the launch programs definition section on each custom page and product page.

ALPHA LAUNCH: Hepatitis virus detection kit

Product name: LyoMorph-X Hepatitis detection kit
Product code (SKU): SD_ID_00007
Format: qPCR and 1-step RT-qPCR - lyophilized and inhibitor-tolerant. Also provided in liquid format.
Potential use cases: Detection of Human Hepatitis through shard-dx™ platforms may provide benefit in high-throughput or point-of-care settings either direct from sample, in a cartridge or from extracted material. Hepatitis may play a role in cancer among several other diseases and is particularly associated with liver diseases.
Development status: Alpha launch. Product in optimisation via established shard-dx™ technology. In-silico development undertaken.
Targets:
- Hepatitis A [all recognised variants as of official 'available (RUO)' launch date]
- Hepatitis B [all recognised variants as of official 'available (RUO)' launch date]
- Hepatitis C [all recognised variants as of official 'available (RUO)' launch date]
Limit of Detection - copies (95%): ≤10 planned
Detection method: Probe
Sample type: Extracted DNA, Extracted RNA, direct blood, direct plasma
Reactions: 96 / 1000
Shipping: Ambient
Number of mastermixes: 1
Number of reactions required per sample: TBD
Positive control inclusion: Yes
Regulatory status: Research Use Only (RUO)
Alpha launch program: Join the shard-dx™ alpha launch program to generate cutting-edge kits alongside us. Find out more on the launch programs definition section on each custom page and product page.

Didn't find your target or configuation? Try Custom.

Custom: Express PCR kits

Low scale (96 reactions) to high scale lyophilized inhibitor tolerant qPCR and 1-step RT-qPCR kits for your target.

Custom: OEM/White-label kits

License from us to gain an edge over the competition with industry-leading performance. Available in your branding.

Custom: Academic collaborations

Collaborate with shard-dx™ to gain access to our innovative technology and support for rapid progression together.

Custom: Clinically focused applications

Your clinical application combined with our technology, completely custom with the option for extensive performance testing.

Request a quote or consultation

Launch Program Definitions

The shard-dx™ product launch pathway allows customers to access the technology earlier with exciting rewards.

PRE-LAUNCH >
OpenClose
ALPHA LAUNCH >
OpenClose
BETA LAUNCH >
OpenClose
AVAILABLE (RUO) >
OpenClose
AVAILABLE (CE-IVD or FDA)
OpenClose

Information

Products

Custom Kits

Contact Us

Location:

BioCity Nottingham, Pennyfoot Street, Nottingham, England, NG1 1GF

Email:

info@shard-dx.com

UK. Registered No 15798577

SHARD DIAGNOSTICS™ and shard-dx™ are trademarks of SHARD DIAGNOSTICS LTD. All rights reserved.